2-n-butyl-9-methyl-8-[1,2,3]triazol-2-yl-9H-purin-6-ylamine and analogues as A2A adenosine receptor antagonists. Design, synthesis, and pharmacological characterization

Journal of Medicinal Chemistry

Volumn 48, Issue 22, 2005, Pages 6887-6896

  Minetti, Patrizia ^b   Tinti, Maria Ornella ^b   Carminati, Paolo ^b   Castorina, Massimo ^b   Di Cesare, Maria Assunta ^b   Di Serio, Stefano ^b   Gallo, Grazia ^b   Ghirardi, Orlando ^b   Giorgi, Fabrizio ^b   Giorgi, Luca ^a   Piersanti, Giovanni ^a   Bartoccini, Francesca ^a   Tarzia, Giorgio ^a  

^a UNIVERSITY OF URBINO   (Italy)

^b Sigma Tau SpA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

2 N BUTYL 9 METHYL 8 [1,2,3]TRIAZOL 2 YL 9H PURIN 6 YLAMINE; 4 [2 [7 AMINO 2 (2 FURYL) 1,2,4 TRIAZOLO[2,3 A][1,3,5]TRIAZIN 5 YLAMINO]ETHYL]PHENOL; 5 AMINO 2 (2 FURYL) 7 (2 PHENYLETHYL)PYRAZOLO[4,3 E][1,2,4]TRIAZOLO[1,5 C]PYRIMIDINE; 8 CYCLOPENTYL 1,3 DIPROPYLXANTHINE; 9 CHLORO 2 (2 FURYL) 5,6 DIHYDRO 5 IMINO 1,2,4 TRIAZOLO[2,3 C]QUINAZOLINE; 9 METHYL 2 PHENETYL 8 [1,2,3]TRIAZOL 2 YL 9H PURIN 6 YLAMINE; ADENOSINE A1 RECEPTOR; ADENOSINE A2A RECEPTOR; ADENOSINE A2A RECEPTOR ANTAGONIST; ADENOSINE A2B RECEPTOR; ADENOSINE A3 RECEPTOR; ADENOSINE RECEPTOR; ISTRADEFYLLINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; BINDING AFFINITY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG DESIGN; DRUG POTENCY; DRUG RECEPTOR BINDING; DRUG SYNTHESIS; EMBRYO; ENZYME INHIBITION; HUMAN; HUMAN CELL; LOCOMOTION; NONHUMAN; RAT;

ADENINE; ANIMALS; CELL LINE; CRICETINAE; CRICETULUS; DRUG DESIGN; HUMANS; IMIDAZOLES; MALE; MODELS, MOLECULAR; MOTOR ACTIVITY; PURINES; RADIOLIGAND ASSAY; RATS; RATS, INBRED F344; RECEPTOR, ADENOSINE A2A; STRUCTURE-ACTIVITY RELATIONSHIP; TRIAZOLES;

EID: 27444442267     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm058018d     Document Type: Article

References (41)

1. (a) Poulsen, S. A.; Quinn, R. J. Adenosine Receptors: New Opportunities for Future Drugs. Bioorg. Med. Chem. 1998, 6, 619-641;
2. (b) Ongini, E.; Fredholm, B. B. Pharmacology of Adenosine A2A Receptors. Trends Pharmacol. Sci. 1996, 17, 364-372;
3. (c) Furlong, T. J.; Pierce, K. D.; Selbie, L. A.; Shine, J. Molecular Characterization of a Human Brain Adenosine A2 Receptor. Mol. Brain Res. 1992, 15, 62-66;
4. (d) Collis, M. G. Evidence for an A1-Adenosine Receptor in the Guinea-Pig Atrium. Br. J. Pharmacol. 1983, 78, 207-212.
5. Fredholm, B. B.; Abbracchio, M. P.; Burnstock, G.; Daly, J. W.; Kendall Harden, T.; Jacobson, K. A.; Leff, P.; Williams, M. VI Nomenclature and Classification of Purinoceptors. Pharmacol. Rev. 1994, 46, 143-156.
6. Kim, D. S.; Palmiter, R. D. Adenosine Receptor Blockade Reverses Hypophagia and Enhances Locomotor Activity of Dopamine-Deficient Mice. Proc. Natl. Acad. Sci. U.S.A. 2003, 100, 1346-1351.
7. (a) Baraldi, P. G.; Cacciari, B.; Spalluto, G.; Borioni, A.; Viziano, M., Dionisotti, S.; Ongini, E. Current Developments of A2A Adenosine Receptor Antagonists. Curr. Med. Chem. 1995, 2, 702-722;
8. (b) Mueller, C. E.; Stein, B. Adenosine Receptor Antagonists: Structures and Potential Therapeutic Applications. Curr. Pharm. Des. 1996, 2, 501-530.
9. (a) Shimada, J.; Koike, N.; Nonaka, H.; Shiozaki, S.; Yanagawa, K.; Kanda, T.; Kobayashi, H.; Ichimura, M.; Nakamura, J.; Kase, H.; Suzuki, F. Adenosine A2A Antagonists with Potent Anti-Cataleptic Activity. Bioorg. Med. Chem. Lett. 1997, 7, 2349-2352;
10. (b) Shiozaki, S.; Ichikawa, S.; Nakamura, J.; Kitamura, S.; Yamada, K.; Kuwana, Y. Actions of Adenosine A2A Receptor Antagonist KW 6002 on Drug-Induced Catalepsy and Hypokinesia Caused by Reserpine or MPTP. Phychopharmacology 1999, 147, 90-95.
11. (a) Baraldi, P. G.; Manfredini, S.; Simoni, D.; Zappaterra, L.; Zocchi, C.; Dionisotti, S.; Ongini, E. Synthesis of New Pyrazolo-[4,3-e]1,2,4- triazolo[1,5-c]pyrimidine and 1,2,3-triazolo[4,5-e]1,2,4-triazolo[1,5-c] pyrimidine Displaying Potent and Selective Activity as A2A Adenosine Receptor Antagonists. Bioorg. Med. Chem. Lett. 1994, 4, 2539-2544;
12. (b) Zocchi, C.; Ongini, E.; Conti, A.; Monopoli, A.; Negretti, A.; Baraldi, P. G.; Dionisotti, S. The Non-Xanthine Heterocyclic Compound SCH 58261 is a New Potent and Selective A2A Adenosine Receptor Antagonist. J. Pharmacol. Exp. Ther. 1996, 276, 398-404;
13. (c) Ongini, E. SCH 58261: a Selective A2A Adenosine Receptor Antagonist. Drug. Dev. Res. 1997, 42, 63-70;
14. (d) Baraldi, P. G.; Fruttarolo, F.; Tabrizi, M. A.; Preti, D.; Romagnoli, R.; El-Kashef, H.; Moorman, A.; Varani, K.; Gessi, S.; Merighi, S.; Borea, P. A. Design, Synthesis, and Biological Evaluation of C9- and C2-Substituted Pyrazolo[4,3-e]-1,2,4-triazolo[1,5-c]pyrimidines as New A2A and A3 Adenosine Receptors Antagonists. J. Med. Chem. 2003, 46, 1229-1241.
15. (a) Caulkett, P. W. R.; Jones, G.; McPartlin, M.; Renshaw, N. D.; Stewart, S. K.; Wright, B. Adenine Isosteres with Bridgehead Nitrogen. Part 1. Two Independent Synthesis of the [1,2,4]triazolo[1,5-a][1,3,5]triazine Ring System Leading to a Range of Substituents in the 2, 5 and 7 Positions. J. Chem. Soc., Perkin Trans. 1 1995, 7, 801-808;
16. (b) Poucher, S. M.; Keddie, J. R.; Singh, P.; Stoggall, S. M.; Caulkett, P. W. R.; Jones, G.; Collis, M. G. The in vitro pharmacology of ZM 241385, a Potent, Non-Xanthine, A2A Selective Adenosine Receptor Antagonist. Br. J. Pharmacol. 1995, 115, 1096-1102.
17. Francis, J. E.; Cash, W. D.; Psychoyos, S.; Ghai, G.; Wenk, P.; Friedmann, R. C.; Atkins, C.; Warren, V.; Furness, P.; Hyun, J. L., Stone, G. A.; Desai, M.; Williams, M. Structure-Activity Profile of a Series of Novel Triazoloquinazoline Adenosine Antagonists. J. Med. Chem. 1988, 31, 1014-1020.
18. (a) Harada, H.; Asano, O.; Hoshino, Y.; Yoshikawa, S.; Matsukura, M.; Kabasawa, Y.; Niijima, J.; Kotake, Y.; Watanabe, N.; Kawata, T.; Inoue, T.; Horizoe, T.; Yasuda, N.; Minami, H. Nagata, K.; Murakami, M.; Nagaoka, J.; Kobayashi, S.; Tanaka, I.; Abe, S. 2-Alkynyl-8-aryl-9-methyladenines as Novel Adenosine Receptor Antagonists: Their Synthesis and Structure-Activity Relationships toward Hepatic Glucose Production Induced via Agonism of the A2B Receptor. J. Med. Chem. 2001, 44, 170-179;
19. (b) Cristalli, G. A2A Adenosine Receptor Antagonists. PCT Patent WO03051882, 2003.
20. (a) Lee, K. S.; Reddington, M. 1,3-Dipropyl-8-cyclopentylxanthine (DPCPX) Inhibition of [3H]N-Ethylcarboxamidoadenosine (NECA) Binding Allows the Visualization of Putative non-A1 Adenosine Receptors. Brain Res. 1986, 368, 394-398;
21. (b) Erickson, R. H.; Hiner, R. N.; Feeney, S. W.; Blake, P. R., Rzeszotarski, W. J.; Hicks, R. P.; Costello, D. G.; Abreu, M. E. 1,3,8-Trisubstituted Xanthines. Effects of Substitution Pattern upon Adenosine Receptor A1/A2 Affinity. J. Med. Chem. 1991, 34, 1431-1435.
22. Baraldi, P. G.; Borea, P. A.; Bergonzoni, M.; Cacciari, B.; Ongini, E.; Recanatini, M.; Spalluto, G. Comparative Molecular Field Analysis (CoMFA) of a Series of Selective Adenosine Receptor A2A Antagonists. Drug Dev. Res. 1999, 46, 126-133.
23. Thompson, R. D.; Secunda, S.; Daly, J. W.; Olsson, R. A. N6,9-Disubstituted Adenines: Potent, Selective Antagonists at the A1 Adenosine Receptor. J. Med. Chem. 1991, 34, 2877-2882.
24. Calenbergh, S. V.; Verlinde, C. L. M. J.; Soenens, J.; De Bruyn, A.; Callens, M.; Blaton, N. M.; Peeters, O. M.; Rozenski, J.; Hol, W. G. J.; Herdewijn, P. Synthesis and Structure-Activity Relationships of Analogues of 2′-Deoxy-2′-(3-methoxybenzamido)adenosine, a Selective Inhibitor of Trypanosomal Glycosomal Glyceraldehyde-3-phosphate Dehydrogenase. J. Med. Chem. 1995, 38, 3838-3849.
25. De Lucca, G. V.; Kim, U. T.; Liang, J.; Cordova, B.; Klabe, R. M.; Garber, S.; Bacheler, L. T.; Lam, G. N.; Wright, M. R.; Logue, K. A.; Erickson-Viitanen, S.; Ko, S. S.; Trainor, G. L.; Nonsymmetric P2/P2′ Cyclic Urea HIV Protease Inhibitors. Structure-Activity Relationship, Bioavailability, and Resistance Profile of Monoindazole-Substituted P2 Analogues. J. Med. Chem. 1998, 41, 2411-2423.
26. Boger, D. L.; Honda, T.; Dang, Q. Total Synthesis of Bleomycin A2 and Related Agents. 2. Synthesis of (-)-Pyrimidoblamic Acid, epi-(+)-Pyrimidoblamic Acid, (+)-Desacetamidopyrimidoblamic Acid, and (-)-Descarboxamidopyrimidoblamic Acid. J. Am. Chem. Soc. 1994, 116, 5619-5630.
27. Hirota, K.; Kitade, Y.; Kanbe Y.; Maki, Y. Convenient Method for the Synthesis of C-Alkylated Purine Nucleosides: Palladium-Catalyzed Cross-Coupling Reaction of Halogenopurine Nucleosides with Trialkylaluminums. J. Org. Chem. 1992, 57, 5268-5270.
28. (a) Van Aerschot, A. A.; Mamos, P.; Weyns, N. J.; Ikeda, S.; De Clercq, E., Herdewijn, P. A. Antiviral Activity of C-Alkylated Purine Nucleosides Obtained by Cross-Coupling with Tetraalkyltin Reagents. J. Med. Chem. 1993, 36, 2938-2942;
29. (b) Labadie, J. W.; Stille, J. K. Mechanisms of the Palladium-Catalyzed Couplings of Acid Chlorides with Organotin Reagents. J. Am. Chem. Soc. 1983, 105, 6129-6137.
30. Cristalli, G.; Eleuteri, A.; Volpini, R.; Vittori, S.; Camaioni E.; Lupidi, G.; Adenosine Deaminase Inhibitors: Synthesis and Structure-Activity Relationships of 2-Hydroxy-3-nonyl Derivatives of Azoles. J. Med. Chem. 1994, 37, 201-205.
31. 1H NMR spectrum of 2-triazolyl derivatives 23b exhibited one singlet at 7.94 ppm characteristic of symmetric compounds, whereas 1-triazolyl derivatives 24b gave two doublets (J = 0.8 Hz) at 7.81 and 8.24 ppm.
32. (a) Reich, M. F.; Fabio, P. F.; Lee, V. J.; Kuck, N. A.; Testa, R. T. Pyrido[3,4-e]-1,2,4-triazines and Related Heterocycles as Potential Antifungal Agents. J. Med. Chem. 1989, 32, 2474-2485;
33. (b) Katner, A. S.; Brown, R. F. A Novel Preparation of Thiazolo[5,4-c]pyridines and the Synthesis of Some Imidazo[4,5-c]pyridines and Oxazolo[4,5-c]pyridines. J. Heterocycl. Chem. 1990, 27, 563-566.
34. Houston, D. M.; Dolence, E. K.; Keller, B. T.; Patel-Thombre, U.; Borchardt, R. T. Potential Inhibitors of S-Adenosylmethionine-Dependent Methyltransferases. 8. Molecular Dissections of Carbocyclic 3-Deazaadenosine as Inhibitors of S-Adenosylhomocysteine Hydrolase. J. Med. Chem. 1985, 28, 467-471.
35. Chorvat, R. J.; Bakthavatchalam, R.; Beck, J. P.; Gilligan, P. J.; Wilde, R. G.; Cocuzza, A. J.; Hobbs, F. W.; Cheeseman, R. S.; Curry, M.; Rescinito, J. P.; Krenitsky, P.; Chidester, D.; Yarem, J. A.; Klaczkiewicz, J. D.; Hodge, C. N.; Aldrich, P. E.; Wasserman, Z. R.; Fernandez, C. H.; Zaczek, R.; Fitzgerald, L. W.; Huang, S. M.; Shen, H. L.; Wong, Y. N.; Chien, B. M.; Quon, C. Y.; Arvanitis, A. Synthesis, Corticotropin-Releasing Factor Receptor Binding Affinity, and Pharmacokinetic Properties of Triazolo-, Imidazo-, and Pyrrolopyrimidines and -pyridines. J. Med. Chem. 1999, 42, 833-848.
36. Oguchi, M.; Wada, K.; Honma, H.; Tanaka, A.; Kaneko, T.; Sakakibara, S.; Ohsumi, J.; Serizawa, N.; Fujiwara, T.; Horikoshi H.; Fujita, T. Molecular Design, Synthesis, and Hypoglycemic Activity of a Series of Thiazolidine-2,4- diones. J. Med. Chem. 2000, 43, 3052-3066.
37. (a) Durcan, M. J.; Morgan, P. F. Evidence for Adenosine A2 Receptor Involvement in the Hypomobility Effects of Adenosine Analogs in Mice. Eur. J. Pharmacol. 1989, 168, 285-290;
38. (b) Popoli, P.; Reggio, R.; Pezzola, A.; Fuxe, K.; Ferre, S. Adenosine A1 and A2A Receptor Antagonists Stimulate Motor Activity: Evidence for an Increased Effectiveness in Aged Rats. Neurosci. Lett. 1998, 251, 201-204;
39. (c) El Yacoubi, M.; Ledent, C.; Parmentier, M.; Costentin, J.; Vaugeois, J.-M. SCH 58261 and ZM 241385 Differentially Prevent the Motor Effects of CGS 21680 in Mice: Evidence for a Functional 'Atypical' Adenosine A2A Receptor. Eur. J. Pharmacol. 2000, 401, 63-77.
40. Salvatore, C. A.; Jacobson, M. A.; Taylor, H. E.; Linden, J.; Johnson, R. G. Molecular Cloning and Characterization of the Human A3 Adenosine Receptor. Proc. Natl. Acad. Sci. U.S.A. 1993, 90, 10365-10369.
41. Knutsen, L. J.; Weiss, S. M. KW 6002 (Kyowa Hakko Kogyo). Curr. Opin. Investig. Drugs 2001, 2, 668-673.